Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia
Aim: To characterize real-world patients with metastatic hormone-sensitive prostate cancer (mHSPC) and treating physicians and evaluate treatment trends and baseline concordance versus guidelines internationally. Materials & methods: Retrospective, cross-sectional data from the Ipsos Global Oncology Monitor database 2018-2020 were used for descriptive analysis of mHSPC patients, treating physicians and treatment utilization. Results: Among the 6198 mHSPC patients from five countries, the most common treatment was either androgen deprivation therapy (ADT) monotherapy or first-generation androgen receptor inhibitor + ADT. Second-generation androgen receptor inhibitor use was only initiating but increasing over the study period. Conclusion: Despite contemporaneous guidelines recommending treatment intensification of ADT in combination with novel antihormonals or docetaxel, 76.1% of reported mHSPC patients received non-guideline-concordant care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 20(2024), 14 vom: 14. März, Seite 903-918 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goebell, Peter J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2023-0814 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368431657 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368431657 | ||
| 003 | DE-627 | ||
| 005 | 20240329000521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2023-0814 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM368431657 | ||
| 035 | |a (NLM)38353055 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goebell, Peter J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To characterize real-world patients with metastatic hormone-sensitive prostate cancer (mHSPC) and treating physicians and evaluate treatment trends and baseline concordance versus guidelines internationally. Materials & methods: Retrospective, cross-sectional data from the Ipsos Global Oncology Monitor database 2018-2020 were used for descriptive analysis of mHSPC patients, treating physicians and treatment utilization. Results: Among the 6198 mHSPC patients from five countries, the most common treatment was either androgen deprivation therapy (ADT) monotherapy or first-generation androgen receptor inhibitor + ADT. Second-generation androgen receptor inhibitor use was only initiating but increasing over the study period. Conclusion: Despite contemporaneous guidelines recommending treatment intensification of ADT in combination with novel antihormonals or docetaxel, 76.1% of reported mHSPC patients received non-guideline-concordant care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a androgen antagonists, therapeutic use | |
| 650 | 4 | |a antineoplastic agents, hormonal, therapeutic use | |
| 650 | 4 | |a antineoplastic combined chemotherapy protocols, therapeutic use | |
| 650 | 4 | |a guideline adherence | |
| 650 | 4 | |a health care surveys, trends | |
| 650 | 4 | |a neoplasm metastasis | |
| 650 | 4 | |a practice guidelines as topic | |
| 650 | 4 | |a practice patterns, physicians' trends | |
| 650 | 4 | |a prostatic neoplasms, drug therapy | |
| 650 | 4 | |a prostatic neoplasms, pathology | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Receptors, Androgen |2 NLM | |
| 650 | 7 | |a Hormones |2 NLM | |
| 700 | 1 | |a Raina, Rutika |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Rege, Sanika |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Ruchit |e verfasserin |4 aut | |
| 700 | 1 | |a Grossman, Jamie Partridge |e verfasserin |4 aut | |
| 700 | 1 | |a Waldeck, A Reginald |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 20(2024), 14 vom: 14. März, Seite 903-918 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:14 |g day:14 |g month:03 |g pages:903-918 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2023-0814 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 14 |b 14 |c 03 |h 903-918 | ||